All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Which AML patients benefit most from venetoclax treatment?
Bookmark this article
The AML Hub was pleased to speak with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, Which AML patients benefit most from venetoclax treatment?
Which AML patients benefit most from venetoclax treatment?
Daver begins by outlining the major impact made by venetoclax and its combinations in improving patient outcomes. He discusses age, comorbidities, and subtypes as factors to consider when selecting treatments. He highlights the similar response rates and lower toxicity of venetoclax compared to other therapies, such as intensive chemotherapy in NPM1-mutated AML. He goes on to explain instances where venetoclax yields superior outcomes and treatment scenarios for "middle-populations", based on individual patient profiles.
More about...
Your opinion matters
14 votes - 2 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox